Biovie (BIVI) Non-Current Assets (2016 - 2026)
Biovie (BIVI) posted Non-Current Assets of $634929.0 for Q1 2026, down 10.81% sequentially from $711859.0 in Q4 2025, and down 32.36% YoY from $938674.0 in Q1 2025.
Biovie (BIVI) Non-Current Assets (2016 - 2026) Analysis & Trends
Biovie has reported Non-Current Assets for 11 years, with the latest figure at $634929.0 in Q1 2026.
- Quarterly Non-Current Assets fell 32.36% year-over-year to $634929.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 28.58% YoY) and the FY2025 annual result came in at $863705.0, down 25.55% from the prior year.
- Non-Current Assets eased to $634929.0 in Q1 2026 per BIVI's latest filing, from $711859.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $1.4 million in Q1 2022 and troughed at $634929.0 in Q1 2026.
- A 5-year average of $1.0 million and a median of $1.1 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets advanced 9.1% in 2024, then slumped 32.36% in 2026.
- Over 5 years, Non-Current Assets stood at $1.2 million in 2022, then slipped by 22.76% to $928536.0 in 2023, then gained by 9.1% to $1.0 million in 2024, then fell by 29.73% to $711859.0 in 2025, then slipped by 10.81% to $634929.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $634929.0, $711859.0, and $788108.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 18.06 Bn |
| 10 | Biovie | 13.80 Mn | 13.80 Mn | - | 608,297.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 608,297.00 |
| Mar 31, 2026 | 634,929.00 |
| Dec 31, 2025 | 711,859.00 |
| Sep 30, 2025 | 788,108.00 |
| Jun 30, 2025 | 863,705.00 |
| Mar 31, 2025 | 938,674.00 |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.16 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 928,536.00 |
| Sep 30, 2023 | 996,210.00 |
| Jun 30, 2023 | 1.06 Mn |
| Mar 31, 2023 | 1.14 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.27 Mn |
| Jun 30, 2022 | 1.33 Mn |
| Mar 31, 2022 | 1.40 Mn |
| Dec 31, 2021 | 1.33 Mn |
| Sep 30, 2021 | 1.38 Mn |